Securities and Exchange Commission (SEC or the commission) announced the issuance of orders instituting administrative proceedings and notice of hearing pursuant to Section 12(j) of the Securities Exchange Act of 1934 to determine whether to revoke or suspend for a period not exceeding twelve months the registration of each class of the securities of Biopharm Asia, Inc for failure to make required periodic filings with the Commission. In the Order, the Division of Enforcement (Division) alleges that the company was delinquent in their required periodic filings with the Commission. In these proceedings, instituted pursuant to Exchange Act Section 12(j), hearings will be scheduled before an Administrative Law Judge. At the hearings, the judge will hear evidence from the Division and company to determine whether the allegations of the Division contained in the Order, which the Division alleges constitute failures to comply with Exchange Act Section 13(a) and Rules 13a-1 and 13a-13 there under, are true. The judge in the proceedings will then determine whether the registrations pursuant to Exchange Act Section 12 of each class of the securities of company should be revoked or suspended for a period not exceeding twelve months. The Commission ordered that the Administrative Law Judge in these proceedings issue an initial decision not later than 120 days from the date of service of the order instituting proceedings.

BioPharm Asia Inc. and Elite Capital Group announced the signing of a consulting agreement for the development of a 1,000-bed Fangzhuang Hospital and Training Center to be located in Fangzhuang, Beijing. BioPharm Asia will serve as master consultant for the project which is scheduled to begin construction in 2012.

On December 8, 2011, BioPharm Asia Inc.'s board of directors appointed Mr. Kenneth Wong as independent director of the company, effective immediately. Formerly, Mr. Wong held senior-level financial positions at Pacific Bridge Medical 1991 - 2002. Mr. Wong supervised the pharmaceuticals practice at Pricewaterhouse Coopers Hong Kong 2002 - 2010.